Biotech

Latest Articles

Basilea ratings $268M BARDA backing for antifungals, antibiotics

.Basilea Pharmaceutica's work establishing brand-new antifungals has actually obtained a significant...

Capricor markets Europe liberties to late-stage DMD therapy for $35M

.Possessing presently scooped up the U.S. civil rights to Capricor Rehabs' late-stage Duchenne muscu...

FDA scraps adcomm for Applied's uncommon illness medication

.After pushing the decision meeting for Applied Rehabs' metabolic problem drug govorestat, the FDA h...

Novo inks $600M NanoVation bargain to analyze genetic drugs ex-liver

.Novo Nordisk is proceeding its own press right into genetic medications, accepting compensate NanoV...

Innovent links cytokine to intestines cancer reactions

.Innovent Biologics has actually created the instance that its checkpoint inhibitor-cytokine blend h...

Merck, Daiichi ADC strikes goal in stage 3 bronchi cancer research study

.A phase 3 test of Daiichi Sankyo and also Merck &amp Co.'s HER3-directed antibody-drug conjugate (A...

Rakovina deepens AI concentrate along with collab to choose cancer cells aim ats

.Five months after Rakovina Therapeutics pivoted toward expert system, the cancer-focused biotech ha...

Ascendis' dwarfism medicine smash hits in period 3, threatens BioMarin

.Ascendis Pharma has emerged as a prospective hazard to BioMarin's Voxzogo, reporting stage 3 growth...

Despite ph. 3 overlook, Alkeus sees road in advance for eye disease property

.Though Alkeus Pharmaceuticals' dental eye ailment property neglected to dramatically lessen geograp...

Kairos goes social with $6M IPO to finance trials of cancer cells medicine

.With a triad of biotechs attacking the Nasdaq on Friday, it was easy to miss out on a smaller-scale...

Vaccine as well as Keytruda combo reliable in squamous tissue carcinoma

.Immune system checkpoint inhibitors are the superheroes of cancer cells therapy. Medications like B...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of significant leadership hirings, firings a...

Regeneron's Opdualag opponent reveals 57% action cost

.Regeneron is actually back with long-lasting consequence for its LAG-3 prevention and also PD-1 pre...

AstraZeneca blog posts information on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early consider the performance of its internal antibody-drug...

iTeos- GSK's TIGIT star reveals relevant enhancement

.After revealing a phase 3 launch based on favorable midstage results, iTeos as well as GSK are actu...

More collective FDA can easily accelerate rare ailment R&ampD: file

.The FDA should be much more available and collaborative to let loose a surge in approvals of rare i...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It is actually an uncommonly hectic Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bic...

Atea's COVID antiviral stops working to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has fallen short another COVID-19 test, but the biotech still store...

Neurocrine's proposal to conserve mental illness prospect neglects

.Neurocrine Biosciences' schizophrenia course pivot has actually failed. The biotech was actually in...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has brought in a late entry to the radioligand gathering, paying one hundred million euros (...